Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

by Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta, Sandra J. Horning, Jeffrey S. Miller, Brad Kahl, Paul M. Sondel
Published 2019-03-01

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy

by Amy K. Erbe, Wei Wang, Patrick K. Reville, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Wendy B. London, Arlene Naranjo, Fangxin Hong, Michael D. Hogarty, John M. Maris, Julie R. Park, Julie R. Park, M. F. Ozkaynak, Jeffrey S. Miller, Andrew L. Gilman, Brad Kahl, Alice L. Yu, Alice L. Yu, Paul M. Sondel, Paul M. Sondel
Published 2017-06-01